10-KPeriod: FY2025

QUEST DIAGNOSTICS INC Annual Report, Year Ended Dec 31, 2025

Filed February 26, 2026For Securities:DGX

Summary

Quest Diagnostics, Inc. (DGX) presented its 2025 fiscal year results in its latest 10-K filing, showcasing its established position in the diagnostic information services market. The company emphasizes its strategy centered on growth and operational efficiency, driven by an industry-leading test menu, collaborations with healthcare providers, leveraging data for population health and value-based care, and adopting innovative technologies like AI and automation. Quest Diagnostics serves a significant portion of the U.S. population, from physicians and hospitals to individual patients, aiming to provide high-quality, convenient, and affordable diagnostic insights. Strategically, Quest Diagnostics continues to focus on its primary customer channels and is expanding its Advanced Diagnostics offerings, including in oncology and neurology. The company has a robust capital deployment framework that includes reinvestment in the business, dividends, and share repurchases, reflecting a commitment to returning value to shareholders. Significant investments in technology, such as AI and a multi-year project to modernize "Order to Cash" processes (Project Nova), are underway to enhance efficiency and customer experience. The company's strong relationships with health plans and extensive network of assets and capabilities position it well within the evolving U.S. healthcare landscape.

Financial Highlights

55 data points
Beta

Revenue

$11.04B

33.2% Gross Margin

Net Income

$992.00M

9.0% Net Margin

EPS (Diluted)

$8.75

Total Assets

$16.23B

Cash & Equivalents

$420.00M

Free Cash Flow

$1.36B

Financial Statements
Beta
Revenue$11.04B
Cost of Revenue$7.37B
Gross Profit$3.67B
SG&A Expenses$1.97B
Operating Expenses$9.48B
Operating Income$1.56B
Net Income$992.00M
EPS (Basic)$8.87
EPS (Diluted)$8.75
Shares Outstanding (Basic)111.00M
Shares Outstanding (Diluted)113.00M

Key Highlights

  • 1Quest Diagnostics generated net revenues of $11.0 billion in 2025, serving approximately one-third of the adult U.S. population annually.
  • 2The company's growth strategy focuses on an industry-leading test menu, partnerships, leveraging data for population health, and adopting AI and automation.
  • 3Quest Diagnostics is a key partner for physicians and hospitals, generating approximately $1.2 billion in revenue from reference testing for hospitals and $800 million from Collaborative Lab Solutions.
  • 4The company is investing in Advanced Diagnostics, particularly in oncology (e.g., Haystack Oncology acquisition for MRD testing) and neurology (e.g., QUEST AD-Detect® for Alzheimer's risk).
  • 5Quest Diagnostics is enhancing its digital capabilities, including its MyQuest® patient portal (over 45 million registered users) and QuestHealth.com for consumer-initiated testing.
  • 6Operational efficiency is a key focus, with initiatives like the 'Invigorate' cost excellence program and 'Project Nova' for 'Order to Cash' process modernization.
  • 7The company maintains a disciplined capital deployment strategy, including returning free cash flow to stockholders through dividends and share repurchases, with a recent 7.5% increase in its quarterly cash dividend.

Frequently Asked Questions

Quest Diagnostics' primary business is providing diagnostic information services through laboratory testing. In 2025, the company generated $11.0 billion in net revenues, driven by a comprehensive menu of routine, non-routine, and advanced clinical testing and anatomic pathology services across various customer channels including physicians, hospitals, and consumers.

Quest Diagnostics is actively investing in and utilizing advanced technologies. This includes leveraging Artificial Intelligence (AI) and automation for operational efficiency, data analytics, and enhanced customer experiences. They have a collaboration with Google Cloud for data management and AI integration. Additionally, they are focused on developing and offering Advanced Diagnostics, such as molecular diagnostics, next-generation sequencing, and specific tests in oncology and neurology, positioning them at the forefront of diagnostic innovation.

Quest Diagnostics faces several key risks, including the evolving U.S. healthcare system and market changes, intense competition from other commercial labs, hospitals, and physician office labs. They are also subject to reimbursement pressures from government payers like Medicare and Medicaid, as well as private health plans, and the potential impact of regulatory changes. Additionally, failures in IT systems, cybersecurity threats, and the inability to innovate or integrate acquisitions effectively pose significant risks.

Quest Diagnostics serves approximately half of the hospitals in the United States through various means, including performing reference testing for hospitals that lack in-house capabilities, helping hospitals operate their labs more efficiently through Collaborative Lab Solutions, and acquiring outreach lab operations. They also engage in joint venture arrangements with health systems, demonstrating a strategic partnership approach to support hospital laboratory strategies and drive demand for their expertise.